Cediranib
Micropapillary Serous Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Micropapillary Serous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hycamtin National Cancer Institute (NCI) | Phase 2/3 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | B |
TAMOXIFEN National Cancer Institute (NCI) | Phase 2/3 | B |
gsk1120212 National Cancer Institute (NCI) | Phase 2/3 | B |
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →